A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT06517758
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Generalized Myasthenia Gravis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Iptacopan — DRUGHard gelatin capsule
- Matching Placebo — OTHERHard gelatin capsule
Study Details
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
Key Dates
- Start date
- Jul 31, 2024
- Status verified
- May 2026
- Primary completion
- Apr 30, 2027
- Completion
- May 27, 2032
Study Design
- Enrollment
- 146 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: IptacopanIptacopan orally for 6 months (double-blind) followed by open-label iptacopan for up to 60 months
- Placebo Comparator: Matching PlaceboPlacebo orally for 6 months (double-blind) followed by open-label iptacopan for up to 60 months
Primary Outcome Measure
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score [ Time Frame: Baseline to Month 6 ]
Central Contacts
- Novartis Pharmaceuticals1-888-669-6682
- Novartis Pharmaceuticals+41613241111
Locations (21)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | Kristy Osgood Suraj Muley (PRINCIPAL_INVESTIGATOR) |
| Fullerton Neuro and Headache Ctr | Fullerton | California | 92835 | Jack H Florin (PRINCIPAL_INVESTIGATOR) |
| SC3 Research Pasadena | Pasadena | California | 91105 | Charles Krinel M Lorraine Purino (PRINCIPAL_INVESTIGATOR) |
| California Pacific Medical Center | Sacramento | California | 94115 | 415-600-3604 Liberty Jenkins (PRINCIPAL_INVESTIGATOR) |
| Neurology Offices Of South Florida | Boca Raton | Florida | 33428 | - |
| Superior Associates in Research LLC | Hialeah | Florida | 33012 | - |
| Augusta University Georgia | Augusta | Georgia | 30912 | Benjamin Barnes (PRINCIPAL_INVESTIGATOR) |
| Hawaii Pacific Neuroscience LLC | Honolulu | Hawaii | 96817 | - |
| University of Chicago Medical Centr | Chicago | Illinois | 60637 | Kourosh Rezania (PRINCIPAL_INVESTIGATOR) |
| Prairie Heart Institute | Springfield | Illinois | 62769 | Raghav Govindarajan (PRINCIPAL_INVESTIGATOR) |
| Mid Atlantic Epilepsy and Sleep Ctr | Bethesda | Maryland | 20817-1807 | Jonathan Ross (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Amanda Guidon (PRINCIPAL_INVESTIGATOR) |
| Henry Ford Health System | Detroit | Michigan | 48202 | 313-916-6781 Kavita Grover (PRINCIPAL_INVESTIGATOR) |
| Duke University Medical Center | Durham | North Carolina | 27710 | Kinjal Patel Shruti Raja (PRINCIPAL_INVESTIGATOR) |
| Neuroscience Research Ctr | Canton | Ohio | 44718 | - |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | - |
| Penn Presbyterian Medical Center | Philadelphia | Pennsylvania | 19104 | Sami Khella (PRINCIPAL_INVESTIGATOR) |
| Vanderbilt University Medical CenterX | Nashville | Tennessee | 37221 | Amanda Peltier (PRINCIPAL_INVESTIGATOR) |
| Nerve and Muscle Center of Texas | Houston | Texas | 77030 | Amy Megerle Aziz Shaibani. (PRINCIPAL_INVESTIGATOR) |
| Central TX Neuro Consultants P A | Round Rock | Texas | 78681 | - |
| Center for Neurological Disorders G | Greenfield | Wisconsin | 53228-1321 | Bhupendra Khatri (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Scottsdale, AZ
Related Studies
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · argenx · Chicago, Illinois
- Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia GravisPHASE2/PHASE3 · Enrolling By Invitation · argenx · Chicago, Illinois
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisPHASE2/PHASE3 · Recruiting · UCB Biopharma SRL · Chicago, Illinois